Product
Imlifidase
Aliases
Hansa Medical-Immunoglobulin G degrading enzyme of Streptococcus pyogenes (HMED-IdeS), IdeS, IgG endopeptidase, IdeS, HMED-IdeS
5 clinical trials
5 indications
Indication
Guillain-Barré SyndromeIndication
Kidney Transplant Failure and RejectionIndication
Kidney Transplant RejectionIndication
Kidney Transplant CandidatesClinical trial
An Open-label, Single Arm, Multi-centre, Phase II Study Investigating Safety, Tolerability, Efficacy, Pharmacodynamics and Pharmacokinetics of Imlifidase in Patients With Guillain-Barré Syndrome, in Comparison With Matched Control PatientsStatus: Completed, Estimated PCD: 2024-02-27
Clinical trial
A Prospective Observational, Long Term Follow up Study of Patients Treated With Imlifidase Prior to Kidney TransplantationStatus: Completed, Estimated PCD: 2023-02-14
Clinical trial
A Prospective, Observational Long-term Follow-up Trial of Kidney Transplant Patients Treated With Imlifidase or Plasma Exchange After an Active/Chronic Active Antibody-Mediated Rejection EpisodeStatus: Terminated, Estimated PCD: 2023-03-30
Clinical trial
An Open Label, Phase II Study to Investigate DSA Rebound in Patients With a Positive Crossmatch, Made Transplantable With ImlifidaseStatus: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
Imlifidase in Living Donor Renal Transplantation Highly Sensitized Recipients (LIVEDES)Status: Not yet recruiting, Estimated PCD: 2026-07-01